Sage Therapeutics Deal History & Licensing Activity
Sage Therapeutics is a biotech headquartered in US. Over the past three years, Sage Therapeutics has been involved in 4 licensing and acquisition transactions, with a primary focus on Small Molecules (4 deals). The company currently has 4 active clinical trials, primarily in Neurology.
Deals (12mo)
1
Active Trials
4
Top Modality
Small Molecules
Focus Area
Neurology
Sage Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Sage Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| depression | Biogen | Small Molecules | Approved | co development | Jul 2025 |
| Zurzuvae (zuranolone) acquisition | Supernus Pharmaceuticals | Small Molecules | Approved | acquisition | Jun 2025 |
| neuroscience portfolio | Supernus | Small Molecules | Approved | acquisition | Jun 2025 |
Sage Therapeutics Pipeline Focus
Therapeutic areas and modalities where Sage Therapeutics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Sage Therapeutics Strategic Signals
Key indicators of Sage Therapeutics's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Sage Therapeutics Clinical Pipeline
Sage Therapeutics has 4 active clinical trials across 4 development phases.
1
Phase 4
1
Unknown
1
Phase 1
1
Phase 2
See How Your Asset Matches Sage Therapeutics's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Neurology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Women's Health Deal Benchmarks
Market sizing, deal terms, and competitive landscape for women's health
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Sage Therapeutics Licensing & Deal Activity
Sage Therapeutics is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Sage Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Sage Therapeutics include Neurology (4 deals and trials), Women's Health (3 deals and trials), and CNS Disorders (3 deals and trials). In terms of modality, Sage Therapeutics has shown particular interest in small molecules, small molecules, neuroactivesteroid.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Sage Therapeutics and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Sage Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.